Investigation into the Origin and Tumoral Mass Correlation of Plasma Epstein–Barr Virus DNA in Nasopharyngeal Carcinoma

Chan, Ka‐Kui; Chan, Anthony T.C.; Leung, Sing Fai; Pang, Jesse C. S.; Wang, Angela Yee-Moon; Tong, Joanna H.M.; To, Ka Fai; Chan, Lisa; Tam, Lai‐Shan; Chung, Nellie Yuk Fei; Zhang, Jun; Lo, Kwok Wai; Huang, Dolly P.; Lo, Y.M. Dennis

doi:10.1373/clinchem.2005.054783

Cited by 47 publications

(35 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings suggest that methylated RASSF1A in the serum reflects the tumor load in HCC patients. A correlation between circulating tumor DNA and tumor load has also been described for other cancers (24,25 ). The apparent lack of a correlation between the serum concentration of RASSF1A at 1 month after the operation and survival may be related to the background concentration of methylated RASSF1A derived from nonmalignant hepatitic liver tissues.…”

Section: Discussionmentioning

confidence: 77%

Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma

Chan¹,

Lai²,

Mok³

et al. 2008

Clinical Chemistry

143

101

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 77%

Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma

Chan¹,

Lai²,

Mok³

et al. 2008

Clinical Chemistry

143

101

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that circulating cell-free plasma EBV DNA originates from the primary tumor, 10 and correlates very well with the tumor mass and tumor metabolic activity by positron emission tomography/CT scan before treatment. 24,25 Once released, plasma EBV DNA exists as short fragments in the circulation instead of within intact virions, which could be eliminated very quickly. 9,10 In addition to the direct cytotoxic effect, systemic chemotherapy might reduce plasma EBV DNA by interfering with other relevant steps.…”

Section: -21mentioning

confidence: 99%

Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy

An¹,

Wang²,

Ding³

et al. 2011

Cancer

138

115

View full text Add to dashboard Cite

BACKGROUND: Plasma Epstein-Barr virus (EBV) DNA is widely used in screening, monitoring, and prediction of relapse in nonmetastatic nasopharyngeal carcinoma (NPC). However, data regarding utility of plasma EBV DNA in metastatic NPC are rare. The current study was to test the prognostic implication of plasma EBV DNA level in metastatic/recurrent NPC patients treated with palliative chemotherapy. METHODS: Plasma EBV DNA level was measured at baseline and thereafter at the start of each treatment cycle in 127 histologically proven metastatic/recurrent NPC patients treated with palliative chemotherapy. Correlations of pre-treatment and post-treatment plasma EBV DNA levels to survival and response were analyzed. RESULTS: Patients with a low pre-treatment plasma EBV DNA level (

show abstract

“…EBV-DNA may be detected in NPC cells (5,6), and cell-free EBV-DNA may be detected in the plasma of patients with NPC (7)(8)(9)(10)(11)(12)(13). Furthermore, the levels of plasma EBV-DNA in recently diagnosed NPC patients have been significantly correlated with tumor volume (14,15), response to treatment (16), tumor clearance (17,18) and tumor recurrence (19)(20)(21). Similarly, it has been observed that a positive post-treatment detection of plasma EBV-DNA is predictive of poor outcomes in terms of subsequent relapse rate, overall survival (OS) and relapse-free survival (RFS) (11,13).…”

Section: Introductionmentioning

confidence: 99%

Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma

et al. 2015

View full text Add to dashboard Cite

Abstract. The level of Epstein-Barr virus DNA (EBV-DNA) in the plasma prior and subsequent to treatment is a reliable biomarker for the screening, diagnosis, monitoring and prognosis of nasopharyngeal carcinoma (NPC). The present retrospective study aimed to determine whether pre-and post-treatment levels of plasma EBV-DNA were predictive of survival in a large sample of patients with NPC. The level of plasma EBV-DNA in 637 NPC patients prior and subsequent to treatment was determined by quantitative polymerase chain reaction. The value of pre-and post-treatment plasma EBV-DNA in predicting the survival of NPC patients was then analyzed. The results revealed that pre-treatment plasma EBV-DNA loads were significantly higher in patients with NPC than those in healthy controls (P<0.001). The percentage of patients with positive plasma EBV-DNA was markedly higher prior to treatment (70.64%; median, 1150 copies/ml; range, 0-9.75x10 6 copies/ml) than following treatment (25.99%; median, 0 copies/ml; range, 0-3.83x10 6 copies/ml) (P<0.001). Patients with a high plasma EBV-DNA load presented with a higher clinical tumor classification, lymph node status, metastatic status and overall cancer stage. The risk of NPC relapse and mortality was higher in patients with pre-treatment plasma EBV-DNA levels of ≥1,500 copies/ml than that in patients with <1,500 copies/ml. Furthermore, the risk of relapse and mortality was higher in patients with positive post-treatment plasma EBV-DNA than in patients with negative post-treatment plasma EBV-DNA. Detectable post-treatment plasma EBV-DNA was the most significant prognostic factor to affect relapse-free survival, whilst metastasis was the prognostic factor with the greatest effect on overall survival. These data indicated that pre-and post-treatment levels of plasma EBV-DNA were able to predict the prognosis of NPC. This finding may provide novel references for research and clinical practice.

show abstract

Investigation into the Origin and Tumoral Mass Correlation of Plasma Epstein–Barr Virus DNA in Nasopharyngeal Carcinoma

Cited by 47 publications

References 13 publications

Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma

Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma

Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy

Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma

Contact Info

Product

Resources

About